Terns Pharmaceuticals, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 21.02 million compared to USD 15.82 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.29 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.91 USD | +5.82% | +7.68% | -24.35% |
Apr. 10 | Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer | CI |
Mar. 27 | UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.35% | 318M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- TERN Stock
- News Terns Pharmaceuticals, Inc.
- Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023